Additional preclinical data support chemoresistance to doxorubicin and cisplatin for CD24+ ovarian cancer [57] and to gemcitabine for CD24+ pancreatic cancer cell lines [58]. This evidence concerns the gene CD24 and familial pancreatic carcinoma.